1. Home
  2. BOBS vs MESO Comparison

BOBS vs MESO Comparison

Compare BOBS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bob's Discount Furniture Inc. Common Stock

BOBS

Bob's Discount Furniture Inc. Common Stock

N/A

Current Price

$16.54

Market Cap

2.4B

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$17.06

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOBS
MESO
Founded
1991
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.1B
IPO Year
2026
2005

Fundamental Metrics

Financial Performance
Metric
BOBS
MESO
Price
$16.54
$17.06
Analyst Decision
Buy
Strong Buy
Analyst Count
11
1
Target Price
$23.73
N/A
AVG Volume (30 Days)
897.6K
181.4K
Earning Date
05-07-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.46
N/A
Revenue
N/A
N/A
Revenue This Year
$12.58
$629.74
Revenue Next Year
$7.43
$30.65
P/E Ratio
$35.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.74
$13.05
52 Week High
$23.11
$21.50

Technical Indicators

Market Signals
Indicator
BOBS
MESO
Relative Strength Index (RSI) 45.20 53.65
Support Level $14.29 $16.56
Resistance Level $16.97 $17.33
Average True Range (ATR) 0.75 0.47
MACD -0.27 -0.04
Stochastic Oscillator 19.55 32.80

Price Performance

Historical Comparison
BOBS
MESO

About BOBS Bob's Discount Furniture Inc. Common Stock

Bobs Discount Furniture Inc operates as a furniture retailer offering a wide variety of merchandise assortments across several categories, including upholstery, case goods, bedding, and other. The company generates the majority of its revenue from the sale of its products through its retail stores.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: